Studies Confirm Anti-PD-1 Activity in MSI-H/dMMR Tumors

]]>(MedPage Today) -- One-third of patients with previously treated advanced cancers associated with high microsatellite instability (MSI-H)/mismatch repair-deficiency (dMMR) responded to single-agent pembrolizumab (Keytruda), two open-label studies...